CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $189.34M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 3.79: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
189.34MUSDvs all stocks (USD)
Revenue (TTM)
116.26MUSDvs all stocks (USD)
Profit Margin
-9.52%Beta
0.2310xvs all stocks
52-Week Change
34.37%vs all stocks
Market Capitalization
189.34MUSDvs all stocks (USD)
Enterprise Value
179.11MUSDvs all stocks (USD)
Forward P/E
31.76xPrice to Sales (TTM)
1.67xPrice to Book (MRQ)
1.46xEnterprise to Revenue
1.54xEnterprise to EBITDA
-26.11xGross Margin
64.15%Profit Margin
-9.52%Operating Margin
-18.53%Return on Assets (TTM)
-4.14%Return on Equity (TTM)
-7.85%Revenue (TTM)
116.26MUSDvs all stocks (USD)
Revenue per Share (TTM)
8.22USDUpdated Jul 9, 2026Quarterly Revenue Growth
13.20%Gross Profit (TTM)
68.12MUSDvs all stocks (USD)
EBITDA (TTM)
-6.86MUSDvs all stocks (USD)
Net Income (TTM)
-11.08MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.16%Operating Cash Flow (TTM)
6.47MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
6.36MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
112.82MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
49.01MUSDFY2025 · Dec 31, 2025Gross Profit
63.81MUSDFY2025 · Dec 31, 2025Operating Income
-11.05MUSDvs all stocks (USD)
Pre-tax Income
-9.31MUSDFY2025 · Dec 31, 2025Income Tax Expense
672.00KUSDFY2025 · Dec 31, 2025Net Income
-10.88MUSDFY2025 · Dec 31, 2025EBIT
-11.05MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-5.32MUSDFY2025 · Dec 31, 2025Research & Development
25.77MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
49.09MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-10.88MUSDFY2025 · Dec 31, 2025Operating Cash Flow
4.44MUSDFY2025 · Dec 31, 2025Free Cash Flow
-2.38MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
57.48MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.08MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-10.88MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
5.73MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-7.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.08MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.17MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
408.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
42.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.10MUSDFY2025 · Dec 31, 2025Capital Expenditures
-6.83MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
600.00KUSDFY2025 · Dec 31, 2025Other Investing Activity
5.83MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.00MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-9.48MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.57MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-11.05MUSDFY2025 · Dec 31, 2025Shares Outstanding
13.36MSharesUpdated Jul 9, 2026Float Shares
11.27MSharesUpdated Jul 9, 2026Shares Short
562.98KSharesUpdated Jul 9, 2026Short Ratio
5.32daysvs all stocks
Short % of Shares Outstanding
5.56%vs all stocks
% Held by Insiders
6.03%vs all stocks
% Held by Institutions
94.60%vs all stocks
Total Cash (MRQ)
41.02MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.08USDUpdated Jul 9, 2026Total Debt (MRQ)
25.74MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1922xCurrent Ratio (MRQ)
4.46xBook Value per Share (MRQ)
10.03USDUpdated Jul 9, 2026Total Assets
190.27MUSDvs all stocks (USD)
Total Current Assets
103.36MUSDFY2025 · Dec 31, 2025Total Liabilities
46.80MUSDFY2025 · Dec 31, 2025Total Non-current Assets
86.91MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
24.90MUSDFY2025 · Dec 31, 2025Total Current Liabilities
21.91MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
57.48MUSDFY2025 · Dec 31, 2025Accounts Receivable
23.69MUSDFY2025 · Dec 31, 2025Inventory
18.79MUSDFY2025 · Dec 31, 2025Accounts Payable
6.04MUSDFY2025 · Dec 31, 2025Short-term Debt
2.05MUSDFY2025 · Dec 31, 2025Long-term Debt
24.20MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
701.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
139.00KUSDFY2025 · Dec 31, 2025Retained Earnings
60.79MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
143.47MUSDvs all stocks (USD)
52-Week Low
7.87USDUpdated Jul 9, 202652-Week High
16.24USDUpdated Jul 9, 202652-Week Change
34.37%vs all stocks
Beta
0.2310xvs all stocks
50-Day MA
14.87USDUpdated Jul 9, 2026200-Day MA
11.50USDUpdated Jul 9, 2026Avg 10-Day Volume
58.76KSharesUpdated Jul 9, 2026Avg 30-Day Volume
74.74KSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-0.7900USDUpdated Jul 9, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.64Profit Margin: -0.10
Financial Health
Altman Z-Score 3.79: safe zoneNotable
Altman Z-Score: 3.79
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $189.34M, lower than 95% of all stocks globallySignificant
Market cap (USD): 189,339,029Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Rightongene Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonix Pharmaceuticals Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Voyager Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Onward Medical
Tier 1ProductionApproval-Gated PipelineRule
Camp4 Therapeutics Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
TaiGen Biopharmaceuticals Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
MediWound Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Corsair Gaming Inc.
1 interpretationDepreciation-Heavy Reported Profit
AMC Networks Inc.
1 interpretationDepreciation-Heavy Reported Profit
Grid Dynamics Holdings, Inc.
1 interpretationDepreciation-Heavy Reported Profit